Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

por Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C
Publicado en Br J Cancer (2014)